Collecting Duct Carcinoma of the Kidney

Collecting duct carcinoma of the kidney is a very rare and very aggressive type of kidney cancer. It starts in the last part of the kidney tubes, called the collecting ducts, which sit deep in the inner part of the kidney (the medulla). These cancer cells are usually high-grade (very abnormal), grow quickly, invade nearby tissue, and often spread (metastasize) to distant organs early, so the outlook is usually poor.

Collecting duct carcinoma (CDC) of the kidney, also called Bellini duct carcinoma, is a very rare and very aggressive type of kidney cancer. It starts in the collecting ducts deep inside the kidney medulla, not in the usual outer part where most renal cell cancers begin. Because it grows fast and spreads early to lymph nodes, lungs, liver, bone, or other organs, many patients are already at an advanced stage when doctors find it. [1] Doctors usually confirm the diagnosis by removing the kidney or taking a biopsy and looking at the tumor cells under a microscope with special stains. [1][2]

CDC is rare (about 0.2–1% of all kidney cancers), so there is no single “standard” treatment like we have for more common renal cell carcinoma. [3] Treatment decisions are usually based on experience with upper urinary tract urothelial cancers and advanced renal cell carcinoma. This means doctors often use surgery plus chemotherapy (usually gemcitabine with a platinum drug like cisplatin), and sometimes targeted drugs or immunotherapy that are approved for kidney cancer in general. [4][5]

Collecting duct carcinoma makes up less than 1% of all renal cell cancers. Because it is so uncommon and looks similar to other kidney tumors, doctors often need special scans, tissue tests, and expert pathologists to make a correct diagnosis. Many people are already at an advanced stage by the time the tumor is found, which is one reason survival is worse than for most other kidney cancers.

Other names

Collecting duct carcinoma is known by several other names in the medical literature. Knowing these names is helpful when you read reports or research papers:

1. Bellini duct carcinoma – This older name comes from the “ducts of Bellini,” an older term for the collecting ducts in the kidney medulla where the tumor starts.

2. Carcinoma of the collecting ducts of Bellini – A longer way of saying the same thing, stressing that the tumor arises from these specific ducts.

3. Collecting duct renal cell carcinoma – This name reminds us it is a subtype of renal cell carcinoma (RCC), but different from the common clear-cell type.

4. Medullary collecting duct carcinoma – This term highlights that the tumor usually sits in the medulla, the inner part of the kidney, not in the outer cortex.

All these names refer to the same basic disease: a rare, aggressive kidney cancer that originates from the epithelial cells lining the distal (last part of the) collecting ducts.

Types

Doctors do not have a perfect, universally agreed “type” system for collecting duct carcinoma because it is so rare. Still, they often group it in a few simple ways that are useful in daily practice:

1. By how far the tumor has spread (stage)

   • Localized: The cancer is only inside the kidney.

   • Locally advanced: The cancer has grown into nearby tissues, veins, or lymph nodes around the kidney.

   • Metastatic: The cancer has spread to distant organs such as lungs, liver, bones, or brain.
     This staging is important because most patients with collecting duct carcinoma unfortunately present with locally advanced or metastatic disease.

2. By microscopic appearance (histologic grade and pattern)
   Under the microscope, the tumor usually shows high-grade tubular or gland-like structures, with cells that look very abnormal and invade in an irregular way through the kidney tissue with a lot of fibrous (desmoplastic) reaction around them. Pathologists often call it “high-grade tubular carcinoma with infiltrative growth.”

3. By purity of the tumor

   • Pure collecting duct carcinoma: The whole tumor is made of collecting duct carcinoma cells.

   • Mixed tumors: Collecting duct carcinoma exists together with another type of renal cell carcinoma in the same kidney.
     Mixed tumors may make diagnosis more difficult and need careful review by an experienced pathologist.

4. By molecular changes (still under study)
   Research shows frequent changes in genes such as NF2 and CDKN2A, along with other pathways related to cell growth and cell cycle control. These molecular types may help guide targeted treatments in the future, but they are not yet standard for everyday care.

Causes and risk factors

For collecting duct carcinoma, doctors believe the exact cause is still unknown. No single strong, proven risk factor has been clearly shown to cause this tumor. However, because it is a kidney cancer, many experts think some of the same risk factors as other kidney cancers may play a role.

1. Older age
   Collecting duct carcinoma tends to occur in middle-aged and older adults, often in people over 50. As we age, our cells collect more DNA damage and have had more time to turn into cancer cells.

2. Male sex
   Men are affected more often than women. Hormones, lifestyle patterns, and differences in exposure to risk factors like smoking may partly explain this imbalance.

3. Black ancestry
   Some series show that collecting duct carcinoma is more frequent in Black individuals compared with white individuals, possibly due to genetic and environmental factors combined.

4. Smoking
   Cigarette smoke contains many chemicals that reach the kidney through the blood and urine. These chemicals can damage kidney cells and raise the risk of kidney cancers in general, so smoking is considered a likely risk factor also for this rare subtype.

5. Obesity
   Extra body fat changes hormone levels and inflammation in the body. This is a known risk factor for kidney cancer in general, and may also contribute to the development of rare subtypes like collecting duct carcinoma.

6. High blood pressure (hypertension)
   Long-term high blood pressure can damage blood vessels and kidney tissue. It is linked to a higher risk of renal cell cancers and may also be relevant to collecting duct carcinoma.

7. Chronic kidney disease (CKD)
   People with long-standing kidney damage have a higher chance of kidney cancers overall. Chronic scarring and inflammation may create an environment that supports cancer cell growth in the kidney medulla.

8. Long-term dialysis
   Patients on dialysis for many years have a greater risk of kidney tumors, especially in shrunken, scarred kidneys. Collecting duct carcinoma is rare, but dialysis-related kidney changes may contribute in some cases.

9. Family history of kidney cancer
   Having close relatives with kidney cancer increases risk, even though most cases still happen by chance. This suggests that shared genes or shared environment may play a role in some families.

10. Inherited cancer syndromes
    Certain inherited syndromes (for example, those involving genes that control cell growth and DNA repair) are linked to kidney cancers. For collecting duct carcinoma, mutations in genes such as NF2 and CDKN2A have been reported, but clear inherited patterns are still being studied.

11. Occupational exposure to chemicals
    Exposure to some industrial chemicals and solvents has been linked with kidney cancers in general. For collecting duct carcinoma, evidence is weaker, but some case reports mention exposure to aromatic amines or other chemicals as possible contributors.

12. Long-term use of some painkillers
    Heavy, long-term use of certain pain medicines (especially older combinations that harmed the kidneys) has been tied to kidney cancer. Chronic injury to the kidney cortex and medulla may indirectly raise the risk of rare tumors as well.

13. Chronic urinary tract inflammation or infections
    Repeated infections or chronic irritation in the urinary system may cause ongoing inflammation near the collecting ducts. Over time, this might increase the chance that damaged cells become cancerous, although data for collecting duct carcinoma specifically are limited.

14. Congenital kidney malformations
    People born with abnormal kidneys (for example, a single kidney or structural abnormalities) may have long-term stress on the remaining tissue. Some case reports of collecting duct carcinoma have appeared in patients with kidney malformations, suggesting a possible link.

15. Previous kidney cancer or pre-cancer lesions
    Very rarely, a person who has had one type of kidney tumor may later develop a collecting duct carcinoma, or the two may exist together in the same kidney. This may reflect shared risk factors or a field of damaged tissue more likely to form multiple cancers.

16. Weakened immune system
    A suppressed immune system, such as in organ transplant recipients or people with advanced HIV, increases the risk of many cancers. While direct data for collecting duct carcinoma are sparse, immune failure likely makes it harder for the body to remove abnormal kidney cells.

17. Previous abdominal radiation therapy
    Radiation can damage DNA in cells inside the radiation field. People who had radiation to the abdomen or spine for other cancers may have a slightly higher risk of kidney tumors many years later.

18. Metabolic syndrome and poor lifestyle
    Lack of physical activity, unhealthy diet, and metabolic problems such as insulin resistance together increase general kidney cancer risk. They may also indirectly raise the risk for rare subtypes like collecting duct carcinoma.

19. Random DNA mutations in collecting duct cells
    In many patients, no clear external risk factor is found. The cancer may start because of random mistakes in DNA replication inside collecting duct cells over time, leading to uncontrolled growth.

20. Unknown or not yet discovered factors
    Because collecting duct carcinoma is so rare, large studies are difficult. It is very likely that there are important risk factors we do not yet know, including specific genetic changes and environmental exposures that future research may uncover.

Symptoms

Collecting duct carcinoma often causes symptoms similar to other kidney cancers, but many people have no complaints until the disease is advanced. Some may even be diagnosed by chance during a scan for another reason.

1. Blood in the urine (hematuria)
   This is the most common symptom. The urine may look pink, red, or cola-colored, or the blood may be visible only under a microscope. It happens when the tumor breaks small blood vessels in the kidney or collecting ducts.

2. Flank or side pain
   People often feel a dull or sometimes sharp pain in the side or back, just below the ribs. This pain comes from the tumor stretching the kidney capsule, invading nearby tissues, or blocking urine flow.

3. A lump or mass in the abdomen or flank
   In some cases, a doctor or the patient can feel a firm mass in the side or abdomen. This usually means the tumor is large or advanced.

4. Unexplained weight loss
   Sudden, unplanned weight loss can happen as the cancer uses a lot of energy and releases substances that change how the body uses food. It is a general sign of many cancers, including collecting duct carcinoma.

5. Tiredness and weakness (fatigue)
   People may feel very tired, weak, or “worn out,” even with normal activities. Cancer-related inflammation, anemia, and poor appetite all play a role in this feeling.

6. Fever without clear infection
   Some patients have recurrent or persistent low-grade fevers. These fevers are caused by cancer-related chemicals (cytokines) and not by bacteria or viruses.

7. Night sweats
   Heavy sweating at night strong enough to soak clothes or bedding can occur. Like fever, this is due to the tumor’s effect on the body’s temperature control.

8. Loss of appetite and early fullness
   People may not feel like eating and may feel full after a small amount of food. This may be caused by tumor-related chemicals, pain, or pressure from a large mass in the abdomen.

9. Swelling in the legs or ankles (edema)
   If the tumor blocks the main kidney veins or lymph vessels, or if kidney function worsens, fluid can build up in the legs and feet, causing swelling.

10. High blood pressure or worsening control of hypertension
    The kidney helps control blood pressure. A tumor can disturb hormone production or blood flow, causing new or harder-to-control high blood pressure.

11. Anemia and pale skin
    Lung and bone marrow effects, chronic blood loss in urine, and reduced kidney hormone (erythropoietin) can lead to anemia. People may notice pale skin, dizziness, or shortness of breath.

12. Bone pain or fractures
    When cancer spreads to bones, it can cause deep bone pain or broken bones (pathologic fractures) after minor injury. This usually means advanced disease.

13. Cough or shortness of breath
    Spread to the lungs can cause chronic cough, chest discomfort, or breathlessness. Sometimes lung nodules are found on a scan before symptoms appear.

14. Jaundice or abdominal swelling from liver spread
    If the cancer spreads to the liver, people may develop yellow skin or eyes (jaundice), dark urine, pale stools, or a swollen abdomen from fluid (ascites).

15. No symptoms at all (incidental finding)
    Some people feel completely well, and the tumor is found accidentally during an ultrasound or CT scan done for other reasons. This is more common when the tumor is small or early.

Diagnostic tests

Overall approach

Because collecting duct carcinoma is rare and can look like other kidney tumors, diagnosis usually needs a combination of clinical exam, blood and urine tests, imaging scans, and finally tissue examination under the microscope. The final, definite diagnosis almost always depends on pathology and special staining of tumor tissue.

Physical examination tests

1. General physical examination
   The doctor asks about symptoms and checks vital signs, weight, and general appearance. They look for clues such as fever, weight loss, or signs of anemia and advanced disease. This broad view helps decide which further tests are needed.

2. Abdominal palpation and mass assessment
   The doctor gently presses on the abdomen and flanks to feel for a mass, tenderness, or swelling. A large kidney tumor may feel like a firm, irregular lump on one side, which raises suspicion of a renal tumor such as collecting duct carcinoma.

3. Costovertebral angle (CVA) tenderness test
   The doctor taps gently over the lower back where the kidneys lie. Pain in this area (CVA tenderness) can suggest kidney problems such as infection, stones, or tumors, and supports the need for imaging.

4. Blood pressure measurement
   Blood pressure is checked because kidney tumors can cause or worsen high blood pressure. New or poorly controlled hypertension in someone with other kidney symptoms strengthens the suspicion of a renal disease.

Manual bedside tests

5. Bimanual kidney ballotment
   The clinician uses both hands to “ballotte” or gently push and feel the kidney between the front and back of the abdomen. A large or abnormally firm kidney may be felt, supporting the presence of a mass that needs imaging.

6. Lymph node palpation
   The neck, armpits, and groin are examined by hand to feel for enlarged lymph nodes. Large, hard nodes can be a sign that kidney cancer, including collecting duct carcinoma, has spread to the lymphatic system.

7. Peripheral edema check
   The doctor presses on the skin over the shins or ankles to look for pitting edema (a dent that stays after pressing). This can suggest kidney dysfunction, vein blockage, or low blood protein, all of which can be related to advanced kidney tumors.

Lab and pathological tests

8. Urinalysis (routine urine test)
   A simple urine test looks for blood, protein, cells, and other substances. Microscopic or visible blood in the urine is a very common sign of kidney tumors and helps guide further imaging.

9. Urine cytology
   A pathologist examines urine under the microscope to look for cancer cells that have shed from the kidney or urinary tract lining. This test can support the diagnosis and helps distinguish collecting duct carcinoma from urothelial cancers.

10. Complete blood count (CBC)
    This blood test measures red cells, white cells, and platelets. Anemia is common in kidney cancer, and rarer problems like very high white cells or low platelets can also appear in advanced disease or with bone marrow involvement.

11. Kidney function tests (creatinine, urea, eGFR)
    These tests show how well the kidneys are working. They help decide if it is safe to use contrast dyes for imaging and whether a person can tolerate surgery or systemic treatments.

12. Liver function tests
    These blood tests look for liver damage or metastasis. Abnormal results can suggest that the cancer has spread or that certain drugs may need dose adjustment.

13. Histopathology of tumor tissue (biopsy or nephrectomy specimen)
    This is the core test for diagnosis. A pathologist looks at tissue removed by needle biopsy or surgery (often radical nephrectomy) under a microscope. They see high-grade tubular structures with infiltrative growth in the renal medulla and surrounding fibrous tissue, typical of collecting duct carcinoma.

14. Immunohistochemistry (IHC) panel
    Special stains are applied to the tumor tissue. Collecting duct carcinoma often shows a pattern of markers that helps distinguish it from other kidney tumors and urothelial carcinoma, such as positivity for some cytokeratins and vimentin with a characteristic staining pattern.

Electrodiagnostic tests

15. Electrocardiogram (ECG)
    While ECG does not diagnose the kidney tumor itself, it records the heart’s electrical activity. It is important before major surgery or chemotherapy to check for heart problems that could affect treatment choices and safety.

16. Cardiac stress test with ECG monitoring (in selected patients)
    If a patient has heart risk factors, doctors may perform a stress test to see how the heart responds to exercise or medication. This supports safe planning of surgery and systemic therapy in people with collecting duct carcinoma.

Imaging tests

17. Renal and urinary tract ultrasound
    Ultrasound is often the first imaging test. It uses sound waves to show the size and shape of the kidneys and may reveal a mass in the medulla or cortex. It is quick, painless, and does not use radiation.

18. Contrast-enhanced CT scan of abdomen and pelvis
    CT with contrast is the main imaging test for kidney tumors. It can show the exact size, location, and shape of the mass, involvement of the renal vein or inferior vena cava, and spread to nearby lymph nodes or organs. Many cases of collecting duct carcinoma are defined by CT features plus pathology.

19. MRI of the kidney and renal vessels
    MRI gives detailed images using magnetic fields instead of X-rays. It is useful when CT contrast cannot be used or when doctors need a clearer look at blood vessels, the renal medulla, or possible invasion into veins and surrounding tissues.

20. Chest CT or whole-body staging scans (CT or PET-CT)
    Because collecting duct carcinoma often spreads early, doctors commonly scan the chest, and sometimes the whole body, to look for metastases in lungs, liver, bones, or other organs. Finding spread helps determine the stage and guides treatment decisions.

Non-pharmacological treatments (therapies and others)

1. Multidisciplinary cancer care team
A multidisciplinary team means kidney cancer is managed by several specialists together: urologic surgeon, medical oncologist, radiation oncologist, radiologist, pathologist, palliative-care doctor, and specialist nurses. They meet to review scans, pathology, and your general health, then build a personalized plan that can include surgery, chemotherapy, radiotherapy, and supportive care. This team approach is very important in a rare, complex cancer like CDC because there is no single standard protocol and decisions must be individualized. [1]

2. Oncologic counseling and shared decision-making
In oncologic counseling, the doctor explains the disease stage, possible treatments, likely benefits, side effects, and realistic goals (cure, control, or comfort). You, your family, and the team decide together which path matches your values. For CDC, this often includes discussing aggressive surgery or chemotherapy versus more comfort-focused care, because prognosis can be poor. Clear, honest communication can reduce anxiety and help people feel more in control even in a difficult situation. [2]

3. Pain management and palliative care
Many patients with advanced CDC have flank pain, bone pain, or discomfort from metastases. Palliative care uses non-drug methods (heat packs, relaxation, nerve blocks, physiotherapy) together with medicines when needed. The goal is to reduce pain and other symptoms, not just at end-of-life but from the time of diagnosis. Good pain control helps people move, sleep, eat, and tolerate cancer treatments better, which can indirectly improve survival and quality of life. [3]

4. Individualized physical activity and rehabilitation
Gentle exercise programs are adapted to the person’s strength and stage of disease. Examples are walking, stretching, light resistance bands, and breathing exercises. Physical activity helps maintain muscle mass, reduce cancer-related fatigue, and support heart and lung function. In CDC, patients may be weak from surgery or chemotherapy; supervised rehab can help them recover faster, reduce falls, and remain independent longer. [4]

5. Nutrition counseling
A registered dietitian helps design meal plans that provide enough calories and protein while respecting kidney function and treatment side effects like nausea or diarrhea. For patients with one kidney or reduced kidney function after surgery, diets may limit salt, processed foods, and excess animal protein while still preventing malnutrition. Good nutrition supports wound healing, immunity, and tolerance to chemotherapy or immunotherapy but does not “cure” the cancer alone. [5]

6. Smoking cessation support
Smoking is a known risk factor for kidney cancers in general and worsens blood vessel and lung health. Quitting smoking with counseling, apps, and (if prescribed by a doctor) nicotine-replacement therapy can improve breathing, wound healing after surgery, and possibly reduce the risk of second cancers or heart disease. For CDC patients, stopping smoking is a realistic way to improve overall health even when the cancer is advanced. [6]

7. Psychological support and psycho-oncology
CDC is rare and aggressive, so fear and depression are common. Psychologists, counselors, or psycho-oncology specialists can provide talk therapy, coping strategies, and group support. These services help patients deal with uncertainty, body-image changes, relationship stress, and fear of recurrence or death. Treating emotional distress can also improve sleep, appetite, and adherence to cancer treatment. [7]

8. Social work and practical support
Oncology social workers help with financial aid, transport to hospital, disability paperwork, and connecting families to community resources. Because CDC often needs frequent hospital visits, this practical support can reduce missed appointments and treatment interruptions. In low-resource settings, social workers may help coordinate charity programs, housing, and caregiver support as well. [8]

9. Physiotherapy for post-surgical recovery
After radical nephrectomy and lymph-node dissection, patients may have pain, stiffness, reduced mobility, and weakness. Physiotherapists teach breathing exercises, safe ways to get out of bed, posture and core-strengthening routines, and targeted exercises that protect the surgical site. This speeds up recovery, lowers the risk of lung infections, and helps people return to daily activities sooner. [9]

10. Occupational therapy and home adaptation
When CDC has spread to bone or brain, patients can have weakness, balance problems, or memory difficulty. Occupational therapists assess the home and suggest grab bars, shower chairs, raised toilet seats, or simple tools to make dressing, bathing, and cooking safer. They also teach energy-conservation techniques to manage severe fatigue. These changes reduce falls and help patients stay independent. [10]

11. Radiotherapy for local control and symptom relief
Although radiotherapy is technically a “treatment,” it is often used in a palliative, symptom-relief way in CDC, for example to control bone pain or prevent spinal cord compression. Focused radiation can shrink painful bone metastases or brain lesions and reduce the need for very high-dose pain medicines. It does not replace surgery or systemic therapy but can be a key supportive tool. [11]

12. Patient education and self-monitoring
Teaching patients and families to monitor for warning signs like new blood in urine, increasing pain, swelling in legs, or shortness of breath helps detect complications early. Simple written action plans explain when to go to the emergency department or call the oncology team. Good education reduces panic, avoids delays in care, and encourages safe use of medicines and supplements. [12]

13. Fertility and sexual-health counseling
Younger patients may be worried about fertility loss from chemotherapy or the emotional impact of body-image changes. Counseling before treatment can explore sperm or egg preservation options where available and give practical advice on intimacy, contraception, and managing treatment-related sexual side effects. Even when cure is unlikely, supporting sexual health can improve quality of life and relationships. [13]

14. Management of anemia and fatigue (non-drug aspects)
Anemia and fatigue can be managed with rest scheduling, light exercise, iron-rich foods when appropriate, and energy-saving strategies, alongside medical treatments like transfusions when needed. Simple lifestyle planning—spreading tasks across the day, using help for heavy work—can reduce exhaustion and make daily life more manageable during CDC treatment. [14]

15. Bone-health strategies (non-drug measures)
If CDC has spread to bone, fall-prevention, safe-lifting techniques, use of walking aids, and home safety checks (removing loose rugs, adding night lights) are essential. These steps reduce fracture risk and protect fragile bones. They complement bone-strengthening drugs and radiotherapy but do not replace them. [15]

16. Sleep hygiene support
Anxiety, pain, and steroids used with chemotherapy can disturb sleep. Simple sleep-hygiene steps—consistent bedtimes, limiting caffeine, quiet and dark bedrooms, relaxation exercises—can improve sleep quality. Better sleep supports immune function, mood, and pain control in people with CDC. [16]

17. Spiritual or faith-based support (if the patient wishes)
Some patients find comfort in spiritual counseling, chaplaincy services, or faith communities. These supports can help people find meaning, cope with suffering, and make difficult decisions about intensive treatment versus comfort-focused care. This is entirely personal and should always respect the patient’s beliefs and preferences. [17]

18. Telemedicine and remote follow-up
Telemedicine visits can reduce travel burden for patients living far from cancer centers. Stable patients can discuss symptoms, lab results, and scan reports with their oncologist by video or phone. This saves energy, reduces cost, and still allows close monitoring of CDC, especially between major imaging studies or treatments. [18]

19. Clinical trial participation (non-standard therapies)
Because CDC is so rare, clinical trials are important to test new combinations of chemotherapy, targeted therapy, and immunotherapy. Trial participation is not “extra medicine” you take alone; it is a structured program with close monitoring. While there is no guarantee of benefit, trials offer access to promising treatments and contribute to knowledge for future patients. [19]

20. Advanced care planning and hospice when appropriate
When CDC is very advanced and no more active treatment is helpful, hospice and advanced care planning become essential. Patients can record their wishes about resuscitation, ICU care, and place of care (home, hospice, or hospital). Hospice focuses on comfort, dignity, and support for the family, not on “giving up.” Planning early often leads to better symptom control and less crisis decision-making. [20]

---

Drug treatments

There is no drug approved specifically “for collecting duct carcinoma.” Most medicines below are approved for renal cell carcinoma or other cancers and may be used off-label in CDC after careful discussion in an expert center.

1. Cisplatin
Cisplatin is a platinum-based chemotherapy that damages cancer-cell DNA so the cells cannot repair themselves and eventually die. It is usually given by IV infusion every 3–4 weeks in cycles. In CDC, cisplatin is commonly combined with gemcitabine and sometimes paclitaxel, based on data from urothelial cancer and small series of CDC patients where responses were seen. Side effects include nausea, vomiting, kidney injury, hearing loss, and nerve damage, so kidney function must be monitored closely. [1]

2. Gemcitabine
Gemcitabine is a nucleoside analogue chemotherapy that blocks DNA synthesis in rapidly dividing cells. It is often given weekly for 2–3 weeks in a 3-week cycle, usually combined with cisplatin. For metastatic CDC, gemcitabine–cisplatin has become a frequently used regimen and has produced partial responses and disease control in small studies and case reports. Major side effects are low blood counts, fatigue, flu-like symptoms, and mild liver enzyme elevations. [2]

3. Paclitaxel
Paclitaxel is a taxane chemotherapy that stabilizes microtubules and stops cells from dividing. Some centers add paclitaxel to gemcitabine–cisplatin to intensify treatment (triplet regimen) in fit patients with metastatic CDC, though evidence is limited. It is given by IV, usually every 3 weeks, and can cause low blood counts, hair loss, peripheral neuropathy, and allergic-type infusion reactions. [3]

4. Carboplatin
Carboplatin is another platinum drug similar to cisplatin but with somewhat different side-effect patterns and often less kidney toxicity. It may be used instead of cisplatin for patients who have weaker kidney function or cannot tolerate cisplatin. Like cisplatin, it forms DNA cross-links to kill cancer cells. It is usually part of doublet or triplet regimens; main side effects are low platelets, anemia, and nausea. [4]

5. Methotrexate (within MVAC-type regimens)
Methotrexate blocks folate metabolism and DNA synthesis. Regimens such as MVAC (methotrexate, vinblastine, doxorubicin, cisplatin), standard in urothelial cancer, have sometimes been used in CDC because of biological similarities. These are intensive regimens with significant risks, including mouth sores, low blood counts, liver toxicity, and kidney injury, and are chosen only for selected, very fit patients. [5]

6. Vinblastine (within MVAC-type regimens)
Vinblastine is a vinca alkaloid that interferes with microtubule formation and cell division. In CDC, it is not used alone, but as part of urothelial-type combinations like MVAC. Side effects include low blood counts, hair thinning, constipation, and nerve damage. Because CDC patients are often frail, this regimen is used cautiously or replaced with gemcitabine–platinum in many centers. [6]

7. Doxorubicin (within MVAC-type regimens)
Doxorubicin is an anthracycline chemotherapy that intercalates into DNA and generates free radicals, leading to cell death. It is cardiotoxic at high cumulative doses, so heart function must be monitored. In CDC, it may be part of aggressive urothelial cancer regimens (such as MVAC) but is not a standard by itself. Fatigue, hair loss, low blood counts, and heart damage at high doses are important risks. [7]

8. Nivolumab (OPDIVO)
Nivolumab is a PD-1 immune checkpoint inhibitor. It “releases the brakes” on T-cells so they can attack cancer cells. It is FDA-approved for advanced renal cell carcinoma alone or in combination with ipilimumab or cabozantinib, given by IV every 2–4 weeks at doses specified in its label. [8] Main side effects are immune-related events such as skin rash, colitis, hepatitis, thyroid problems, and lung inflammation, which require steroids if severe. [9]

9. Pembrolizumab (KEYTRUDA)
Pembrolizumab is another PD-1 inhibitor approved for advanced renal cell carcinoma in combination with axitinib or lenvatinib. It is given as an IV infusion every 3 or 6 weeks, at fixed doses described in the FDA label. [10] In CDC, it may be used off-label for metastatic disease, especially within clinical trials or when no other options are available. Immune-related side effects are similar to nivolumab and require careful monitoring. [11]

10. Ipilimumab (YERVOY) in combination with nivolumab
Ipilimumab is a CTLA-4 inhibitor used with nivolumab for some patients with intermediate- or poor-risk advanced renal cell carcinoma. It further boosts T-cell activation. The combination is given in several IV cycles, then nivolumab is continued alone. [12] Side effects can be stronger than with single-agent therapy, including severe colitis, hepatitis, endocrine problems, and skin reactions. Its use in CDC is based on extrapolation from RCC data and is usually limited to expert centers or trials.

11. Cabozantinib (CABOMETYX)
Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks VEGF, MET, and AXL pathways, which are important for tumor blood supply and growth. It is FDA-approved for advanced renal cell carcinoma, given orally, typically 60 mg once daily, with adjustments for side effects. [13] In CDC, it may be used off-label after or with immunotherapy. Common side effects are diarrhea, hand–foot skin reactions, high blood pressure, fatigue, and mouth sores.

12. Sunitinib (SUTENT)
Sunitinib is a VEGF-receptor TKI approved for advanced renal cell carcinoma. It is usually taken as 50 mg orally once daily on a “4 weeks on, 2 weeks off” schedule. [14] It works by blocking signals that tumors use to grow blood vessels. In CDC, sunitinib has been tried in small case series with mixed results but can be considered after chemotherapy in selected patients. Side effects include fatigue, diarrhea, high blood pressure, hand–foot syndrome, and low blood counts.

13. Pazopanib (VOTRIENT)
Pazopanib is another VEGF-pathway TKI approved for adults with advanced renal cell carcinoma, usually taken as 800 mg once daily on an empty stomach. [15] Like other TKIs, it reduces tumor blood supply. In rare CDC cases, it may be tried after standard options. Main side effects include liver toxicity, high blood pressure, diarrhea, hair color changes, and fatigue, so liver tests and blood pressure must be checked regularly.

14. Sorafenib (NEXAVAR)
Sorafenib is a multikinase inhibitor targeting RAF and VEGF receptors, approved for advanced renal cell carcinoma. The usual recommended dose is 400 mg orally twice daily on an empty stomach. [16] It may be used in CDC by extrapolation, especially when other TKIs are not available. Side effects include diarrhea, hand–foot skin reaction, rash, high blood pressure, and risk of heart ischemia.

15. Lenvatinib plus everolimus
Lenvatinib is a VEGF-pathway TKI, and everolimus is an mTOR inhibitor. This combination is approved for patients with advanced renal cell carcinoma after prior anti-angiogenic therapy. [17] Lenvatinib is taken orally (for RCC usually 18 mg daily when combined with everolimus), and everolimus is taken as 5 mg daily. This dual approach attacks both blood-vessel growth and cell-growth pathways. Side effects include hypertension, diarrhea, mouth sores, high blood sugar, and increased infection risk.

16. Everolimus (single-agent)
Everolimus is an mTOR inhibitor that slows cell growth and metabolism. It is used for advanced RCC after failure of VEGF-targeted therapy. In CDC, it may have a role in heavily pretreated, selected patients, but evidence is very limited. The drug is taken orally once daily and can cause mouth ulcers, high cholesterol, high blood sugar, low blood counts, and increased infection risk. [18]

17. Bevacizumab (with gemcitabine-platinum)
Bevacizumab is an antibody against VEGF that blocks tumor blood-vessel formation. Some small series in CDC and related tumors have used bevacizumab combined with gemcitabine and platinum drugs, with variable results. [19] It is given as an IV infusion every 2–3 weeks. Main side effects include high blood pressure, bleeding, blood-clot risk, and poor wound healing, so it is used carefully around surgery.

18. Supportive antiemetics (e.g., ondansetron)
Powerful antiemetic drugs like ondansetron are not cancer treatments, but they are essential to help patients tolerate cisplatin-based regimens by preventing severe nausea and vomiting. They are usually taken or infused around chemotherapy days. Better nausea control prevents dehydration, electrolyte imbalance, and treatment delays, which indirectly supports effective cancer therapy. [20]

19. Growth-factor support (e.g., G-CSF such as filgrastim)
Granulocyte colony-stimulating factors help the bone marrow recover white blood cells after intensive chemotherapy. These injections reduce infection risk and allow doctors to keep chemotherapy on schedule. They do not treat CDC directly but are important supportive drugs in aggressive regimens like gemcitabine–cisplatin or MVAC. Side effects can include bone pain and very rarely spleen problems. [21]

20. Bone-modifying agents (e.g., zoledronic acid, denosumab)
If CDC spreads to bone, drugs that strengthen bone and reduce fracture risk may be used. Zoledronic acid (an IV bisphosphonate) or denosumab (a subcutaneous antibody) help prevent skeletal-related events such as fractures, spine compression, and the need for radiation or surgery to bone. They can cause low calcium and rare jaw-bone problems, so dental checks and calcium/vitamin D supplementation (if safe) are important. [22]

---

Dietary molecular supplements (supportive, not curative)

Always ask your oncologist before starting any supplement. Some can interfere with chemotherapy or targeted therapy.

Below are general examples used to support nutrition and metabolism in cancer care. Evidence in CDC specifically is limited; they do not replace standard treatment.

1. Protein supplements (whey or plant-based)
High-quality protein powders can help people who eat poorly because of nausea, early fullness, or weight loss. Protein provides amino acids needed to maintain muscle, repair tissues, and support immune cells during chemotherapy or after surgery. Dosing is usually individualized to reach daily protein targets (often 1.0–1.5 g/kg/day total from diet plus supplements if kidney function allows). They are mixed into shakes or soft foods and should be monitored in patients with reduced kidney function. [1]

2. Omega-3 fatty acids (fish oil or algae-based)
Omega-3s may help reduce inflammation and cancer-related weight loss (cachexia) in some patients. Typical studied doses are around 1–3 g/day of EPA/DHA combined, but the exact dose must be tailored to kidney function, bleeding risk, and other medicines. Omega-3s may mildly lower triglycerides and support heart health but can increase bleeding risk at high doses, especially with TKIs or anticoagulants. [2]

3. Vitamin D (if deficient)
Vitamin D helps with bone health, immune function, and muscle strength. Many cancer patients are deficient. If blood tests show low levels, doctors may prescribe vitamin D3 in doses such as 800–2000 IU/day or higher short-term regimens according to guidelines. Supplementation supports bones, especially in patients receiving bone-modifying drugs or long-term steroids, but dosing must consider kidney function and calcium levels to avoid high calcium. [3]

4. Calcium (carefully, and only if needed)
Calcium supplements may be recommended if dietary intake is low and bone-strengthening drugs are used. Typical doses are 500–1000 mg/day from food plus supplements, but they must be adjusted in patients with kidney problems or high blood calcium. Adequate calcium supports bone mineralization and may reduce fracture risk when combined with vitamin D and physical activity. [4]

5. Probiotics (selected strains)
Probiotics are “good” bacteria used to support gut health, especially in patients with diarrhea from chemotherapy, antibiotics, or TKIs. Doses vary by product, commonly billions of CFUs per day. Some evidence suggests they may reduce antibiotic-associated diarrhea and support gut barrier function, but in severely immunocompromised patients there is a small risk of infection, so they must be used only under medical supervision. [5]

6. B-complex vitamins (if deficient)
B vitamins (B1, B2, B6, B12, folate) are important for energy metabolism and nerve function. Cancer patients with poor intake may become deficient, which worsens fatigue and neuropathy. Low-dose B-complex supplements can restore normal levels, but high-dose individual B vitamins should not be taken without medical advice, especially together with methotrexate or other chemo that interacts with folate. [6]

7. Oral rehydration solutions (electrolyte drinks)
Medically designed oral rehydration solutions contain balanced water, sodium, potassium, and glucose to correct dehydration from vomiting or diarrhea caused by chemotherapy or TKIs. They are not simple sports drinks. The goal is to prevent kidney damage and keep blood pressure stable. Amount and frequency depend on fluid status and kidney function. [7]

8. Branched-chain amino acids (BCAAs)
BCAA supplements may be used to support muscle mass in cachectic patients, though evidence is mixed. They supply leucine, isoleucine, and valine, which are important for muscle protein synthesis. Typical doses in studies range from a few grams to several tens of grams per day, but they must be supervised by a dietitian, especially if kidney function is impaired. [8]

9. Fiber supplements (psyllium, partially hydrolyzed guar gum)
Soluble fiber supplements can help manage both constipation and mild diarrhea by normalizing stool consistency. They also support gut microbiome health. Doses usually start low and increase gradually with plenty of water. In patients with bowel obstruction or very low fluid intake, fiber is unsafe, so medical advice is essential. [9]

10. Antioxidant-rich food concentrates (under guidance)
Some patients use berry or vegetable concentrates for extra antioxidants. Whole foods are preferred, but for those who cannot eat enough fruits and vegetables, standardized concentrates may help fill gaps. However, very high-dose antioxidant supplements can, in theory, interfere with some chemotherapies that rely on oxidative stress to kill tumor cells, so they should never be used without oncologist approval. [10]

---

Immunity-supporting / regenerative medical treatments

1. G-CSF (filgrastim, pegfilgrastim)
Granulocyte colony-stimulating factors are injections used after chemotherapy to help the bone marrow recover white blood cells. They reduce the risk of serious infections (neutropenia) and allow doctors to keep chemotherapy at effective doses. They are given under the skin for a few days after each cycle. Side effects include bone pain and, rarely, spleen problems. These are prescription-only agents used under strict supervision. [1]

2. Erythropoiesis-stimulating agents (ESAs) in selected patients
In patients with symptomatic anemia from chemotherapy who cannot receive frequent blood transfusions, ESAs may be used to stimulate red-blood-cell production. They are injections given on a scheduled basis. They can improve fatigue but may slightly increase the risk of blood clots or tumor progression in some cancers, so their use is limited and carefully weighed against risks. [2]

3. Autologous or allogeneic stem-cell transplantation (rare, experimental for CDC)
For CDC, stem-cell transplantation is not standard, but in very rare research settings, high-dose chemotherapy followed by stem-cell rescue may be discussed, especially if the biology resembles other transplant-responsive cancers. The patient’s own or donor stem cells are infused after high-dose chemo to re-build the bone marrow. This is highly intensive, with serious risks of infection, organ damage, and graft-versus-host disease, and is only done in specialized centers within trials. [3]

4. Immunotherapy combinations (nivolumab + ipilimumab, pembrolizumab + TKIs)
Combining checkpoint inhibitors (PD-1 plus CTLA-4 blockade, or PD-1 plus VEGF-targeted TKIs) creates a stronger immune attack on the tumor. These regimens are approved for advanced renal cell carcinoma and sometimes used off-label in CDC, often in clinical trials. They may provide durable responses in a subset of patients but also carry higher risk of serious immune-mediated side effects that can affect almost any organ. [4]

5. Bone-marrow–supportive care with transfusions
Packed red blood cell and platelet transfusions are standard hospital treatments to quickly correct severe anemia or low platelets caused by chemotherapy or the cancer itself. They do not cure CDC but prevent life-threatening complications like heart strain, severe fatigue, or internal bleeding. Transfusions are carefully matched and monitored to avoid reactions. [5]

6. Future cellular therapies (research only)
Experimental treatments such as engineered T-cells or personalized vaccines are being studied in many cancers. For CDC, because it is rare, data are very limited, but in the future these “regenerative” or cellular approaches may offer new options. At present they should only be used inside regulated clinical trials with full informed consent and long-term follow-up. [6]

---

Surgeries (procedures and why they are done)

1. Radical nephrectomy with lymph-node dissection
Radical nephrectomy removes the entire kidney, surrounding fat, and often nearby lymph nodes. This is the main treatment for localized CDC and sometimes for bulky tumors with limited spread. The goal is to remove all visible cancer, provide tissue for accurate diagnosis, and reduce tumor burden before systemic therapy. Surgery can be open or laparoscopic, depending on tumor size and location. [1]

2. Nephron-sparing (partial) nephrectomy (rare in CDC)
Partial nephrectomy removes only the tumor and a rim of normal kidney tissue. Because CDC usually arises deep in the medulla and is aggressive, partial nephrectomy is less common. It may be considered only for very small, localized lesions or when preserving kidney function is absolutely critical. The goal is to balance oncologic safety with kidney preservation. [2]

3. Metastasectomy (removal of limited metastases)
In selected patients with a single or few metastases (for example, in lung or bone), surgeons may remove those metastatic lesions if the rest of the disease is controlled. The idea is to reduce tumor burden, relieve symptoms (such as pain or risk of fracture), and possibly prolong survival in highly selected cases. Evidence is limited but this approach is sometimes used in kidney cancers generally. [3]

4. Palliative orthopedic surgery for bone metastases
If CDC has weakened a bone so much that it is at high risk of breaking, orthopedic surgeons may stabilize it with rods, plates, screws, or joint replacement. This prevents painful fractures, preserves mobility, and reduces the risk of spinal cord compression when vertebrae are involved. It is usually combined with radiotherapy and bone-strengthening drugs. [4]

5. Palliative urinary diversion or nephrostomy
If the tumor obstructs urine flow, surgeons or interventional radiologists can place stents or nephrostomy tubes to drain urine from the kidney. This relieves pain, prevents infection, and can improve kidney function so that chemotherapy becomes safer. Though it does not shrink the tumor, it prevents life-threatening complications from urinary blockage. [5]

---

Prevention tips (general kidney-cancer risk reduction)

There is no guaranteed way to prevent CDC because it is rare and not fully understood. However, general kidney-cancer prevention and healthy-kidney strategies include:

1. Do not smoke and avoid second-hand smoke – smoking is a major risk factor for kidney cancers. [1]

2. Keep blood pressure under control with lifestyle and medicines if needed.

3. Maintain a healthy body weight through balanced diet and physical activity.

4. Limit long-term use of painkillers, especially non-steroidal anti-inflammatory drugs (NSAIDs), unless your doctor advises otherwise.

5. Stay well hydrated, unless your kidney specialist advises fluid restriction.

6. Avoid unnecessary exposure to industrial chemicals and heavy metals (like trichloroethylene) using proper workplace protection.

7. Manage chronic kidney disease and cystic kidney diseases with regular nephrology follow-up.

8. Control diabetes and high cholesterol, which affect kidney and blood-vessel health.

9. Attend regular follow-up if you have known genetic syndromes associated with kidney cancers (for example, hereditary RCC syndromes) so tumors can be found early.

10. See a doctor promptly for blood in the urine, persistent flank pain, or unexplained weight loss, so serious causes can be investigated early. [2]

---

When to see doctors urgently

You should seek urgent medical help (emergency or immediate clinic visit) if you have CDC or are at risk and notice:

• New or worsening blood in the urine (pink, red, or cola-colored urine).

• Sudden severe flank or back pain that does not improve.

• High fever, chills, or feeling very unwell, which may mean infection when your immunity is low from chemotherapy.

• Shortness of breath, chest pain, or coughing up blood, which could indicate lung clots, metastases, or heart problems.

• New weakness, difficulty walking, or loss of bladder/bowel control, which could be signs of spinal cord compression from bone metastases.

• Confusion, severe headache, or seizures, which may suggest brain involvement or treatment side effects.

For any new symptom during systemic therapy (especially checkpoint inhibitors or TKIs), it is safer to contact your oncology team early. [1]

---

Things to eat and things to avoid

(Always adapt to your kidney function, other illnesses, and diet advice from your nephrologist or dietitian.)

What to eat (general guidance)

1. Plenty of vegetables and fruits – especially colorful ones (spinach, carrots, berries) for vitamins, minerals, and fiber, within any potassium limits your kidney doctor gives you.

2. Moderate portions of lean protein (fish, skinless poultry, eggs, tofu, lentils) to support healing and muscle, adapted to your kidney function.

3. Whole grains such as oats, brown rice, or whole-wheat bread (unless potassium/phosphorus are restricted).

4. Healthy fats like olive oil, nuts, seeds, and avocado in small amounts for energy and heart health.

5. Plenty of safe fluids (water or oral rehydration solutions) if your doctor does not limit fluids.

6. Small, frequent meals if you have poor appetite or nausea.

7. Soft, easy-to-swallow foods (soups, smoothies, yogurt) on days when you feel very tired.

8. Iron-rich foods like lean meat, beans, and fortified cereals if anemia is a problem (checking with your doctor first).

9. Fermented foods such as yogurt with live cultures, if tolerated, to help gut health.

10. Foods that match cultural preferences to help you actually eat enough, adjusted for salt and spice as needed. [1]

What to avoid or limit

1. Very salty foods (chips, instant noodles, pickles, processed meats) that worsen blood pressure and fluid retention.

2. Highly processed meats (bacon, sausages, smoked meats) that increase kidney and heart strain.

3. Sugary drinks (sodas, energy drinks) that add empty calories and can worsen diabetes.

4. Excessive red meat and organ meat, which may burden the kidneys and increase cardiovascular risk.

5. Excessive alcohol, which affects the liver, increases falls, and can worsen some drug side effects.

6. Unpasteurized dairy and raw or undercooked meats, especially when white blood cells are low, because infection risk is higher.

7. Large doses of herbal or “immune-boosting” supplements without oncologist approval, as they can interact with chemo, TKIs, or immunotherapy.

8. Grapefruit and Seville oranges if you take certain TKIs (like sunitinib, pazopanib, cabozantinib), because they change how the liver processes these drugs. [2]

9. Very high-protein fad diets that can harm kidney function if only one kidney remains.

10. Extreme “detox” or crash diets, which can lead to malnutrition and weaken your body during treatment.

---

Frequently asked questions

1. Is collecting duct carcinoma the same as usual kidney cancer?
No. CDC is a rare type of kidney cancer that starts in the collecting ducts deep inside the kidney, not in the outer part like typical clear-cell renal cell carcinoma. It behaves more aggressively and often spreads earlier than common kidney cancers. [1]

2. How rare is this cancer?
CDC is very rare, making up roughly 0.2–1% of all kidney cancers. Because it is so uncommon, many doctors may see only a few cases in their entire career, and most treatment guidance comes from small studies and expert opinion. [2]

3. What symptoms usually appear first?
Common early symptoms are blood in the urine, flank or back pain, and sometimes a lump in the abdomen. Many people also notice weight loss, fatigue, or fever. Unfortunately, these symptoms may appear when the disease is already advanced. [3]

4. Can collecting duct carcinoma be cured?
If CDC is found very early and fully removed with surgery, some patients can live many years and may be cured. However, many cases are diagnosed at an advanced stage, where cure is difficult and treatment focuses on controlling the disease and relieving symptoms as long as possible. [4]

5. What is the usual treatment plan?
For localized disease, radical nephrectomy is usually the first step. For advanced or metastatic disease, treatment often includes platinum-based chemotherapy (like gemcitabine–cisplatin) and may also include targeted therapy or immunotherapy, sometimes in clinical trials. Supportive and palliative care are important at every stage. [5]

6. Why are clinical trials important in this cancer?
Because CDC is so rare, we do not yet know the best combination and sequence of treatments. Clinical trials help test new drugs or combinations in a structured way. Participating may give you access to promising therapies and also helps future patients by improving medical knowledge. [6]

7. Are immunotherapy drugs like nivolumab or pembrolizumab useful?
Immune checkpoint inhibitors are approved for advanced renal cell carcinoma and have shown benefits in many kidney-cancer patients. For CDC specifically, evidence is limited to small series and case reports, but some responses have been seen, especially when these drugs are combined with targeted therapies. Their use in CDC is usually in expert centers or trials. [7]

8. How long can someone live with collecting duct carcinoma?
Outcomes vary widely. Some patients with early-stage disease do well for many years after surgery. For metastatic CDC, published studies report median overall survival often less than 1 year, though some patients live longer, especially if they respond well to chemotherapy or newer therapies. These are group averages; your doctors can explain what they mean for you personally. [8]

9. Does diet or supplements cure this cancer?
No. No food or supplement can cure CDC. A healthy diet and carefully chosen supplements can support strength, immune function, and tolerance of treatment, but they must always be used alongside, not instead of, proven medical therapies. [9]

10. Can I keep working during treatment?
Some people can continue working part-time or from home, especially early in treatment, while others need full-time rest and recovery. This depends on the type of job, the intensity of chemotherapy or targeted therapy, and how your body reacts. Your care team and employer can help you plan adjustments and rest periods. [10]

11. Is this cancer hereditary?
Most CDC cases are not known to be strongly hereditary, but rare familial kidney-cancer syndromes exist. If you are very young at diagnosis or have a strong family history of kidney cancer, genetic counseling may be recommended to check for inherited conditions and to advise relatives on screening. [11]

12. What if my kidney function is already poor?
If you have reduced kidney function, your team will carefully choose imaging tests, surgery type, and chemotherapy drugs, and adjust doses to protect the remaining kidney tissue. Sometimes carboplatin is chosen instead of cisplatin, and some TKIs may be preferred over others depending on how your kidneys work. [12]

13. Can radiotherapy cure collecting duct carcinoma?
Radiotherapy alone usually does not cure CDC, but it can play an important role in controlling pain or preventing complications from bone or brain metastases. In selected cases, stereotactic, highly focused radiation may help control small areas of disease. It is usually used together with surgery or systemic therapies. [13]

14. How often will I need scans?
Scan frequency depends on stage and treatment. After surgery, surveillance imaging may be done every few months at first, then less often. During systemic therapy, scans are typically done every 2–3 months to check if the cancer is shrinking, stable, or growing. Your team will adjust timing based on your symptoms and how treatments are going. [14]

15. Where should I be treated?
Because CDC is so rare and complex, it is best to be treated or at least seen at a center with experience in rare kidney cancers, if possible. Local doctors and major cancer centers can often share care: you might receive some treatments locally but have your plan reviewed by a specialist center. This “shared care” model combines expertise with convenience. [15]

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: February 09, 2025.